Apellis Pharmaceuticals announced that retina specialist Philip Ferrone, M.D., will join the company as Chief Medical Retina Advisor, effective March 18. Ferrone will continue to serve as the director of clinical research at Vitreoretinal Consultants in New York. He is a past president of the ASRS and has been on its board of directors for 18 years.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on APLS:
- Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- EyePoint appoints Ribeiro as Chief Medical Officer
- Apellis price target raised to $89 from $87 at UBS
- Biotech Alert: Searches spiking for these stocks today
